ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
내장 리슈만편모충증 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 5.8%의 성장률(CAGR)로 13억 3,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 백신 개발에 대한 투자 증가, 세계 질병 감시 프로그램 강화, 민관 파트너십 증가, 소외된 열대성 질병에 대한 자금 지원 확대, 유전자 기반 치료법의 발전 등에 기인합니다. 이 기간 동안 예상되는 주요 동향으로는 CRISPR 기반 유전자 편집, AI 기반 신약 개발, 나노기술을 통한 약물전달, 기생충 분석을 위한 차세대 시퀀서, 조기 발견을 위한 웨어러블 바이오센서, 의료 공급망 관리를 위한 블록체인 기술, 스마트폰 기반 진단 도구, 스마트폰 기반 진단 도구, 의료 공급망 관리를 위한 블록체인 기술 등이 있습니다. 스마트폰 기반 진단 도구, 맞춤형 치료 연구를 위한 3D 바이오프린팅 등이 있습니다.
영양실조 유병률의 증가는 향후 몇 년 동안 내장 리슈만편모충증 시장의 성장을 촉진할 것으로 예상됩니다. 영양실조는 최적의 신체 기능에 필요한 필수 영양소의 섭취 부족 또는 불균형으로 인해 발생하는 건강 상태를 말합니다. 이러한 증가는 영양가 높은 식품에 대한 접근을 제한하고 영양 부족과 면역 체계를 저하시키는 미량영양소 결핍을 초래하는 식량 불안으로 인해 크게 증가했습니다. 면역력이 떨어지면 내장 리슈만편모충증과 같은 감염성 질환에 걸리기 쉽습니다. 영양 부족은 신체의 병원균에 대한 방어 능력을 저하시켜 심각한 질병 및 관련 합병증을 유발할 가능성을 높입니다. 예를 들어, 2024년 7월 이탈리아에 본부를 둔 유엔 관련 기관인 식량농업기구는 2021년 7억 8,700만 명에서 2022년 7억 2,380만 명으로 영양 부족 인구가 증가했다고 보고했습니다. 그 결과, 영양실조 발생률의 증가는 내장 리슈만편모충증 시장의 성장에 박차를 가하고 있습니다.
내장 리슈만편모충증 시장의 주요 업체들은 특히 이 질병이 유행하는 지역에서 치료 효과를 높이고 환자 접근성을 확대하기 위해 개선된 항기생충제와 같은 첨단 치료 옵션 개발에 우선순위를 두고 있습니다. 항기생충제는 기생충의 중요한 과정을 억제하여 기생충의 숙주 내 성장, 번식, 생존을 억제함으로써 기생충 감염을 치료하도록 설계되어 있습니다. 예를 들어, 2024년 2월 인도 제약회사 Zydus Lifesciences Limited는 세계보건기구(WHO)의 사전승인을 획득한 밀테포신의 원료의약품(API)과 제제 모두에 대해 칼라자르(Kalaazal)로 알려진 리슈만편모충증 치료제로 승인받았습니다. 미르테포신은 경구용 항기생충제로 기생충의 세포막과 대사 과정을 파괴하여 기생충을 죽입니다. 이 때문에 내장 리슈만편모충증.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 내장 리슈만편모충증PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 내장 리슈만편모충증시장 : 성장률 분석
세계의 내장 리슈만편모충증시장 실적 : 규모와 성장, 2019-2024
세계의 내장 리슈만편모충증시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 내장 리슈만편모충증 전체 시장(TAM)
제6장 시장 세분화
세계의 내장 리슈만편모충증시장 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
구충제
항진균제
기타 치료법
세계의 내장 리슈만편모충증시장 진단 방법별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
혈청학적 검사
분자 검사
현미경 검사
배양 방법
세계의 내장 리슈만편모충증시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
경구
주사제
기타 투여 경로
세계의 내장 리슈만편모충증시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
온라인 약국
소매 약국
세계의 내장 리슈만편모충증시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
홈케어
전문 클리닉
기타 최종사용자
세계의 내장 리슈만편모충증시장, 항기생충제 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
5값안티몬
미르테호신
파로모마이신
시타마크인
병용요법
세계의 내장 리슈만편모충증시장 항진균제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
안호테리신 B
리포솜 암포테리신 B(암비솜)
아졸
에키노칸딘
폴리엔
세계의 내장 리슈만편모충증시장, 기타 치료법 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
면역요법
단클론항체
백신 기반 접근법
광역학 요법
유전자 치료
제7장 지역별·국가별 분석
세계의 내장 리슈만편모충증시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 내장 리슈만편모충증시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
내장 리슈만편모충증시장 : 경쟁 구도
내장 리슈만편모충증시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
Novartis AG Overview, Products and Services, Strategy and Financial Analysis
GSK plc Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Takeda Pharmaceutical Company Limited
Gilead Sciences Inc.
Sun Pharmaceutical Industries Ltd.
Dr. Reddy's Laboratories
Aurobindo Pharma Limited
Cipla Limited
Zydus Lifesciences Limited
Glenmark Pharmaceuticals Limited
Alkem Laboratories Ltd
Xellia Pharmaceuticals
Knight Therapeutics Inc
Gufic Biosciences Ltd.
United Biotech Private Limited
DNDi
TLC
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
내장 리슈만편모충증시장 2029 : 새로운 기회를 제공하는 국가
내장 리슈만편모충증시장 2029 : 새로운 기회를 제공하는 부문
내장 리슈만편모충증시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Visceral leishmaniasis, also known as kala-azar, is a serious parasitic disease caused by Leishmania species and transmitted through the bite of an infected sandfly. It primarily affects internal organs such as the liver, spleen, and bone marrow, leading to symptoms such as persistent fever, weight loss, anemia, and organ enlargement. If left untreated, the disease can be fatal, highlighting the importance of early detection and prompt treatment.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary treatment options for visceral leishmaniasis include antiparasitic, antifungal, and other types of therapies. Antiparasitic treatments consist of drugs or interventions that specifically target and eliminate parasites by interfering with their biological functions, thereby inhibiting their growth, reproduction, or survival. Diagnosis involves a range of methods, including serological tests, molecular techniques, microscopy, and culture-based approaches. Treatments are administered via various routes, including oral, injectable, and other alternative delivery methods. Distribution channels include hospital pharmacies, online pharmacies, and retail pharmacies. The treatments are utilized by different end users such as hospitals, home care settings, specialty clinics, and other healthcare facilities.
The visceral leishmaniasis market research report is one of a series of new reports from The Business Research Company that provides visceral leishmaniasis market statistics, including visceral leishmaniasis industry global market size, regional shares, competitors with a visceral leishmaniasis market share, detailed visceral leishmaniasis market segments, market trends and opportunities, and any further data you may need to thrive in the visceral leishmaniasis industry. This visceral leishmaniasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The visceral leishmaniasis market size has grown strongly in recent years. It will grow from$1.00 billion in 2024 to $1.06 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth during the historic period can be credited to several factors, including a rising disease burden, increased government funding, the introduction of amphotericin B, the development of miltefosine, expanded awareness campaigns, enhanced healthcare access in endemic areas, and the formation of public-private partnerships.
The visceral leishmaniasis market size is expected to see strong growth in the next few years. It will grow to$1.33 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The anticipated growth in the forecast period can be attributed to increased investment in vaccine development, strengthened global disease surveillance programs, rising public-private partnerships, greater funding for neglected tropical diseases, and advancements in gene-based therapies. Key trends expected during this period include CRISPR-based gene editing, AI-driven drug discovery, nanotechnology-enhanced drug delivery, next-generation sequencing for parasite analysis, wearable biosensors for early detection, blockchain technology for medical supply chain management, smartphone-based diagnostic tools, and 3D bioprinting for personalized treatment research.
The growing prevalence of malnutrition is expected to drive the expansion of the visceral leishmaniasis market in the coming years. Malnutrition refers to a health condition caused by insufficient or imbalanced intake of essential nutrients needed for optimal body function. This rise is largely attributed to food insecurity, which restricts access to nutritious food, resulting in undernourishment and micronutrient deficiencies that compromise the immune system. A weakened immune system increases the body's vulnerability to infections such as visceral leishmaniasis. Nutritional deficiencies reduce the body's ability to defend against pathogens, thereby raising the likelihood of severe disease and related complications. For instance, in July 2024, the Food and Agriculture Organization, a UN-affiliated agency based in Italy, reported that the number of undernourished individuals increased to 723.8 million in 2022, up from 708.7 million in 2021. As a result, the increasing incidence of malnutrition is fueling the growth of the visceral leishmaniasis market.
Key players in the visceral leishmaniasis market are prioritizing the development of advanced treatment options, such as improved antiparasitic medications, to enhance therapeutic efficacy and broaden patient access, especially in regions where the disease is endemic. Antiparasitic drugs are designed to treat parasitic infections by interfering with the parasite's vital processes, thereby inhibiting its growth, reproduction, or survival inside the host. For example, in February 2024, Zydus Lifesciences Limited, an Indian pharmaceutical firm, secured World Health Organization (WHO) prequalification for both the active pharmaceutical ingredient (API) and formulation of miltefosine for treating leishmaniasis, also known as kala-azar. Miltefosine is an oral antiparasitic that disrupts the parasite's cell membrane and metabolic processes, ultimately leading to its death. This makes it a highly effective oral option for treating visceral leishmaniasis.
In January 2023, Gilead Sciences Inc., a U.S.-based biopharmaceutical company specializing in visceral leishmaniasis treatments, renewed its collaboration with the World Health Organization (WHO) to expand access to therapies for this condition. As part of the partnership, Gilead Sciences is donating 304,700 vials of AmBisome (liposomal amphotericin B) to increase the availability of essential medicines for treating visceral leishmaniasis in countries with a high disease burden. This initiative supports global efforts to combat and eliminate the disease. The WHO, a specialized agency headquartered in Switzerland, plays a critical role in the prevention, control, and eradication of visceral leishmaniasis through coordinated health programs and strategic global initiatives.
Major players in the visceral leishmaniasis market are Pfizer Inc., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories, Aurobindo Pharma Limited, Cipla Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Ltd, Xellia Pharmaceuticals, Knight Therapeutics Inc, Gufic Biosciences Ltd., United Biotech Private Limited, DNDi, and TLC.
North America was the largest region in the visceral leishmaniasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in visceral leishmaniasis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the visceral leishmaniasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The visceral leishmaniasis market consists of revenues earned by entities by providing services such as drug development and distribution, vector control programs, and research and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The visceral leishmaniasis market also includes sales of antileishmanial drugs, vaccines, vector control insecticides, recombinant antigen-based diagnostics, and polymerase chain reaction (PCR)-based detection kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Visceral Leishmaniasis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on visceral leishmaniasis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for visceral leishmaniasis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The visceral leishmaniasis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment: Antiparasitic; Antifungal; Other Treatments
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Visceral Leishmaniasis Market Characteristics
3. Visceral Leishmaniasis Market Trends And Strategies
4. Visceral Leishmaniasis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Visceral Leishmaniasis Growth Analysis And Strategic Analysis Framework
5.1. Global Visceral Leishmaniasis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Visceral Leishmaniasis Market Growth Rate Analysis
5.4. Global Visceral Leishmaniasis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Visceral Leishmaniasis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Visceral Leishmaniasis Total Addressable Market (TAM)
6. Visceral Leishmaniasis Market Segmentation
6.1. Global Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antiparasitic
Antifungal
Other Treatments
6.2. Global Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Serological Tests
Molecular Tests
Microscopy
Culture Methods
6.3. Global Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
Other Routes Of Administration
6.4. Global Visceral Leishmaniasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
6.5. Global Visceral Leishmaniasis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End-Users
6.6. Global Visceral Leishmaniasis Market, Sub-Segmentation Of Antiparasitic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pentavalent Antimonials
Miltefosine
Paromomycin
Sitamaquine
Combination Therapy
6.7. Global Visceral Leishmaniasis Market, Sub-Segmentation Of Antifungal, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Amphotericin B
Liposomal Amphotericin B (AmBisome)
Azoles
Echinocandins
Polyenes
6.8. Global Visceral Leishmaniasis Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunotherapy
Monoclonal Antibodies
Vaccine-Based Approaches
Photodynamic Therapy
Gene Therapy
7. Visceral Leishmaniasis Market Regional And Country Analysis
7.1. Global Visceral Leishmaniasis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Visceral Leishmaniasis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Visceral Leishmaniasis Market
9.1. China Visceral Leishmaniasis Market Overview
9.2. China Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Visceral Leishmaniasis Market
10.1. India Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Visceral Leishmaniasis Market
11.1. Japan Visceral Leishmaniasis Market Overview
11.2. Japan Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Visceral Leishmaniasis Market
12.1. Australia Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Visceral Leishmaniasis Market
13.1. Indonesia Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Visceral Leishmaniasis Market
14.1. South Korea Visceral Leishmaniasis Market Overview
14.2. South Korea Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Visceral Leishmaniasis Market
15.1. Western Europe Visceral Leishmaniasis Market Overview
15.2. Western Europe Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Visceral Leishmaniasis Market
16.1. UK Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Visceral Leishmaniasis Market
17.1. Germany Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Visceral Leishmaniasis Market
18.1. France Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Visceral Leishmaniasis Market
19.1. Italy Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Visceral Leishmaniasis Market
20.1. Spain Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Visceral Leishmaniasis Market
21.1. Eastern Europe Visceral Leishmaniasis Market Overview
21.2. Eastern Europe Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Visceral Leishmaniasis Market
22.1. Russia Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Visceral Leishmaniasis Market
23.1. North America Visceral Leishmaniasis Market Overview
23.2. North America Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Visceral Leishmaniasis Market
24.1. USA Visceral Leishmaniasis Market Overview
24.2. USA Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Visceral Leishmaniasis Market
26.1. South America Visceral Leishmaniasis Market Overview
26.2. South America Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Visceral Leishmaniasis Market
27.1. Brazil Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Visceral Leishmaniasis Market
28.1. Middle East Visceral Leishmaniasis Market Overview
28.2. Middle East Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Visceral Leishmaniasis Market
29.1. Africa Visceral Leishmaniasis Market Overview
29.2. Africa Visceral Leishmaniasis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Visceral Leishmaniasis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Visceral Leishmaniasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Visceral Leishmaniasis Market Competitive Landscape And Company Profiles
